Sensorineural hearing loss (SNHL) is a serious public health problem which affects 1-3% per hundred live born babies in developed countries. The congenital cytomegalovirus (CMV) infection is its most important non-genetic cause. The evaluation of the effectiveness of future programs of anti-CMV vaccination requires an assessment of the present costs of SNHL. Direct costs for the Italian public system were calculated per prosthesis child until his full age and turned out to add up to 260,000 euro. Private costs are difficult to be assessed and anyhow are highly dependent from the socio-economic level. This preliminary assessment suggests that the vaccination would be cost-saving if SNHL cases due to congenital CMV were more than 21 per year, corresponding to a congenital infection prevalence higher than 0.21%o.
Sordità neurosensoriale infantile: valutazione dell'impatto economico nella prospettiva della prevenzione vaccinale dei casi da infezione congenita da Cytomegalovirus / M.S. Caroppo, M.L. Tanzi, L. Veronesi, U. Ambrosetti, C. Cislaghi, M. Barbi. - In: ANNALI DI IGIENE MEDICINA PREVENTIVA E DI COMUNITÀ. - ISSN 1120-9135. - 17:4(2005), pp. 307-311.
Sordità neurosensoriale infantile: valutazione dell'impatto economico nella prospettiva della prevenzione vaccinale dei casi da infezione congenita da Cytomegalovirus
M.S. CaroppoPrimo
;U. Ambrosetti;M. BarbiUltimo
2005
Abstract
Sensorineural hearing loss (SNHL) is a serious public health problem which affects 1-3% per hundred live born babies in developed countries. The congenital cytomegalovirus (CMV) infection is its most important non-genetic cause. The evaluation of the effectiveness of future programs of anti-CMV vaccination requires an assessment of the present costs of SNHL. Direct costs for the Italian public system were calculated per prosthesis child until his full age and turned out to add up to 260,000 euro. Private costs are difficult to be assessed and anyhow are highly dependent from the socio-economic level. This preliminary assessment suggests that the vaccination would be cost-saving if SNHL cases due to congenital CMV were more than 21 per year, corresponding to a congenital infection prevalence higher than 0.21%o.File | Dimensione | Formato | |
---|---|---|---|
Ann Ig 2005.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.76 MB
Formato
Adobe PDF
|
1.76 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.